Sugi Predict

Sugi Predict / Compounds / SCHEMBL717374

SCHEMBL717374

SCHEMBL717374

COC(=O)CC(=O)CN1CCOCC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ TSHR P16473 2/20 0.48
▸ ALOX15 P16050 2/20 0.48
▸ GLA P06280 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.44
▸ ALDH1A1 P00352 6/20 0.43
▸ GAA P10253 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2826608 0.86 KDM4E (0.55) KDM4EHSD17B10SMN1; SMN2TSHRALOX15
SCHEMBL24653168 0.86 TSHR (0.53) KDM4EHSD17B10SMN1; SMN2TSHRALOX15
Hydrochloric Acid SCHEMBL28036233 0.85 KDM4E (0.53) KDM4EHSD17B10SMN1; SMN2TSHRALOX15
SCHEMBL28292220 0.83 KDM4E (0.49) KDM4EHSD17B10SMN1; SMN2TSHRALOX15
SCHEMBL19379914 0.81 ALDH1A1 (0.49) KDM4ESMN1; SMN2TDP1ALDH1A1GAA
SCHEMBL21436218 0.80 KDM4E (0.67) KDM4EHSD17B10SMN1; SMN2TSHRALOX15
SCHEMBL11528008 0.77 KDM4E (0.70) KDM4EHSD17B10SMN1; SMN2TSHRALOX15
SCHEMBL17892556 0.76 TDP1 (0.50) KDM4EHSD17B10SMN1; SMN2TSHRALOX15
SCHEMBL8570721 0.76 KDM4E (0.57) KDM4EHSD17B10SMN1; SMN2TSHRALOX15
SCHEMBL12534284 0.76 GLA (0.45) KDM4EHSD17B10SMN1; SMN2TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111491935-B Novel analogs as modulators of androgen and glucocorticoid receptors 昂科斯特拉公司 2023-08-22 — — CN disclosed
EP-3707143-B9 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS ONCOSTELLAE S L (ES) 2023-04-12 — — EP disclosed
EP-3707143-B1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS ONCOSTELLAE S L (ES) 2022-12-28 — — EP disclosed
US-11453660-B2 Androgen receptor and glucocorticoid receptor modulators ONCOSTELLAE, S.L. 2022-09-27 — — US disclosed
US-20200325123-A1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS ONCOSTELLAE, S.L. (ES) 2020-10-15 — — US disclosed
EP-3707143-A1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS Oncostellae, S.L. (ES) 2020-09-16 — — EP disclosed
EP-3480201-A1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS Oncostellae, S.L. (ES) 2019-05-08 — — EP disclosed
US-20170275270-A1 BENZYL SUBSTITUTED INDAZOLES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-28 — — US disclosed
US-20170275270-A1 BENZYL SUBSTITUTED INDAZOLES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-28 — — US disclosed
US-20170275270-A1 BENZYL SUBSTITUTED INDAZOLES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-28 — — US disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 — — US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 — — US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 — — US disclosed
CN-102015641-A Heterocyclic compound TAKEDA PHARMACEUTICAL 2011-04-13 — — CN disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 — — EP disclosed
US-7074784-B2 Nitrogen compounds such as methyl 4-(2-chloro-4-fluorophenyl) -2-(3,5-difluoropyridin-2-yl)-6-(4-morpholinylmethyl)-1,4-dihydropyrimidine -5-carboxylate, with mixtures of lamivudine and interferons, used as viricides; hepatitis Goldmann, Siegfried (DE) 2006-07-11 — — US disclosed
EP-1265889-B1 MEDICAMENTS AGAINST VIRAL DISEASES BAYER HEALTHCARE AG (DE) 2004-06-16 — — EP disclosed
US-20030232842-A1 Medicaments against viral diseases SUNSHINE LAKE PHARMA CO., LTD. (CN) 2003-12-18 — — US disclosed
EP-1265889-A1 MEDICAMENTS AGAINST VIRAL DISEASES Bayer Aktiengesellschaft (DE) 2002-12-18 — — EP disclosed
WO-2001068640-A1 MEDICAMENTS AGAINST VIRAL DISEASES BAYER AKTIENGESELLSCHAFT (DE) 2001-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885HSD17B10 691/4885SMN1; SMN2 1051/4885
US-20030232842-A1 Medicaments against viral diseases HAVCR2, ENTPD5, TYMP KDM4E 3556/4885HSD17B10 2715/4885SMN1; SMN2 4280/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885HSD17B10 691/4885SMN1; SMN2 1051/4885
US-20170275270-A1 BENZYL SUBSTITUTED INDAZOLES UGT2B7, CYP3A43, CYP3A7 KDM4E 2538/4885HSD17B10 1130/4885SMN1; SMN2 1782/4885
US-20200325123-A1 NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS NR5A1, AR, NR3C1 KDM4E 3692/4885HSD17B10 111/4885SMN1; SMN2 4176/4885
US-11453660-B2 Androgen receptor and glucocorticoid receptor modulators AR, NR5A1, NR3C1 KDM4E 3611/4885HSD17B10 109/4885SMN1; SMN2 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.